Lucas Tramujas
Overview
Explore the profile of Lucas Tramujas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
965
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Tomazini B, Tramujas L, Junior F, Gomes S, Negrelli K, Murinize G, et al.
PLoS One
. 2024 Feb;
19(2):e0299197.
PMID: 38394069
Background: Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent in vitro activity against SARS-CoV-2 virus. The safety and efficacy of halofuginone in Covid-19 patients has not...
12.
de Barros E Silva P, do Nascimento C, Pedrosa R, Arruda Nakazone M, do Nascimento M, de Araujo Melo L, et al.
Sci Rep
. 2024 Feb;
14(1):4222.
PMID: 38378735
There is limited contemporary prospective real-world evidence of patients with chronic arterial disease in Latin America. The Network to control atherothrombosis (NEAT) registry is a national prospective observational study of...
13.
Tramujas L, Junior F, Biasi Cavalcanti A, Pompilio C
Arq Bras Cardiol
. 2023 Apr;
120(4):e20220539.
PMID: 37098989
No abstract available.
14.
Maia I, Marcadenti A, Veiga V, Miranda T, Gomes S, Carollo M, et al.
Lancet Reg Health Am
. 2023 Mar;
20:100466.
PMID: 36908503
Background: Repurposed drugs for treatment of new onset disease may be an effective therapeutic shortcut. We aimed to evaluate the efficacy of repurposed antivirals compared to placebo in lowering SARS-CoV2...
15.
Tramujas L, Judice M, Becker A
J Vasc Bras
. 2022 Oct;
21:e20200217.
PMID: 36259054
Background: Venous thromboembolism is an entity that encompasses both deep vein thrombosis and pulmonary thromboembolism. Although protocols for the diagnosis of these diseases are well defined, there is evidence of...
16.
Albuquerque A, Eckert I, Tramujas L, Butler-Laporte G, McDonald E, Brophy J, et al.
Clin Microbiol Infect
. 2022 Jul;
29(1):13-21.
PMID: 35863630
Background: Randomized controlled trials (RCT) established the mortality reduction by tocilizumab (Actemra), baricitinib (Olumiant), and sarilumab (Kevzara) in hospitalized COVID-19 patients. However, uncertainty remains about which treatment performs best in...
17.
Albuquerque A, Tramujas L, Sewanan L, Williams D, Brophy J
JAMA Netw Open
. 2022 Feb;
5(2):e220548.
PMID: 35226077
Importance: A World Health Organization (WHO) meta-analysis found that tocilizumab was associated with reduced mortality in hospitalized patients with COVID-19. However, uncertainty remains concerning the magnitude of tocilizumab's benefits and...
18.
Lopes R, de Barros E Silva P, Furtado R, Macedo A, Bronhara B, Damiani L, et al.
Lancet
. 2021 Jun;
397(10291):2253-2263.
PMID: 34097856
Background: COVID-19 is associated with a prothrombotic state leading to adverse clinical outcomes. Whether therapeutic anticoagulation improves outcomes in patients hospitalised with COVID-19 is unknown. We aimed to compare the...
19.
Cavalcanti A, Zampieri F, Rosa R, Azevedo L, Veiga V, Avezum A, et al.
N Engl J Med
. 2020 Jul;
383(21):2041-2052.
PMID: 32706953
Background: Hydroxychloroquine and azithromycin have been used to treat patients with coronavirus disease 2019 (Covid-19). However, evidence on the safety and efficacy of these therapies is limited. Methods: We conducted...
20.
Franco L, Kindermann A, Tramujas L, Kock K
Rev Bras Ortop
. 2016 Nov;
51(5):509-514.
PMID: 27818970
Objective: To analyze factors associated with mortality among elderly people hospitalized in a single-center regional hospital due to femoral fractures. Methods: This was a retrospective cohort study. Patients aged 60...